Sanara MedTech (NASDAQ:SMTI) & Sunny Optical Technology (Group) (OTCMKTS:SNPTF) Critical Analysis

Sunny Optical Technology (Group) (OTCMKTS:SNPTF) and Sanara MedTech (NASDAQ:SMTI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Sunny Optical Technology (Group) and Sanara MedTech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunny Optical Technology (Group)	$5.33 billion	1.70	$375.45 million	N/A	N/A
Sanara MedTech	$101.88 million	2.13	-$9.66 million	($4.22)	-5.78

Sunny Optical Technology (Group) has higher revenue and earnings than Sanara MedTech.

Profitability

This table compares Sunny Optical Technology (Group) and Sanara MedTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunny Optical Technology (Group)	N/A	N/A	N/A
Sanara MedTech	-36.79%	-21.33%	-7.05%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sunny Optical Technology (Group) and Sanara MedTech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunny Optical Technology (Group)	0	0	0	0	0.00
Sanara MedTech	1	0	2	0	2.33

Sanara MedTech has a consensus price target of $41.00, indicating a potential upside of 68.03%. Given Sanara MedTech’s stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than Sunny Optical Technology (Group).

Insider & Institutional Ownership

8.1% of Sanara MedTech shares are held by institutional investors. 42.6% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Sunny Optical Technology (Group) has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Summary

Sanara MedTech beats Sunny Optical Technology (Group) on 7 of the 12 factors compared between the two stocks.

About Sunny Optical Technology (Group)

Sunny Optical Technology (Group) Company Limited, an investment holding company, engages in designing, researching, developing, manufacturing, and selling optical and optical related products, and scientific instruments. The company's Optical Components segment offers glass spherical and aspherical lenses, handset lens sets, vehicle lens sets, security surveillance lens sets, and other lens sets. Its Optoelectronic Products segment comprise handset camera modules, three dimensional optoelectronic products, vehicle modules, and other optoelectronic modules. The company's Optical Instruments segment includes microscopes and intelligent inspection equipment for testing. Its optoelectronic-related products are used in handsets, digital cameras, vehicle imaging and sensing systems, security surveillance systems, virtual reality/augmented reality, and robots, which are combined with optical, electronic, algorithm, and mechanical technologies. In addition, the company engages in the research and development of infrared and semiconductor technologies; trading of optical instruments and optoelectronics products; property leasing activities; and development, service, and consultation of technology; provision of financing services; and import and export agency services. It operates primarily in the People's Republic of China, rest of Asia, Europe, North America, and internationally. The company was founded in 1984 and is headquartered in Yuyao, China.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.